NFKB1 and colorectal carcinoma: Accumulating evidence suggests that 15-LOX-1 inhibits inflammation-driven colorectal tumorigenesis and suppresses signaling pathways that play a major role in chronic inflammation-promoting CRC, such as TNF-α, IL-1β/NF-κB, and IL-6/STAT3 pathways [110].